Development of diagnostic and disease-monitoring biomarkers of bradykinin-mediated angioedema with or without C1-inhibitor deficiency in hereditary angioedema - HAE BMA study

Takeda Pharmaceutical Company Limited0 个研究点目标入组 60 人开始时间: 2021年8月6日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•Exclusion criteria for each group shall be set as below. Patients/individuals who meet any of the criteria below for the relevant group will be excluded from the study. [HAE type 1/2 group and HAE type 3 group] 1.Patients receiving C1-INH preparations for the 7 days prior to the time of blood collection 2.Patients receiving berotralstat hydrochloride for the 20 days prior to the time of blood collection 3.Patients receiving lanadelumab for the 70 days prior to the time of blood collection 4.Patients who are judged by the principal investigator or the subinvestigator to be inappropriate as study participants [Healthy group] 1. Individuals who have been diagnosed with inflammatory diseases 2. Individuals who have been diagnosed with allergic diseases 3. Individuals who have not been administered a therapeutic drug continuously for 10 days or more within the 60 days* prior to the time of blood collection 4. Individuals who are judged by the principal investigator or the subinvestigator to be inappropriate as study participants

发起方